सिर और गर्दन का कैंसर
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
कहाँ जाना है
इस trial के लिए 1 hospital भारत में मरीज़ ले रहा है।
रजिस्ट्री समरी (तकनीकी)
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.
Sponsor: NATCO फार्मा लिमिटेड.
NCT05283226 ऑन ClinicalTrials.gov
Last updated on the registry 23 Jan 2026 · read by us 20 Oct 2026